Patents Issued in August 15, 2019
  • Publication number: 20190248846
    Abstract: Disclosed are novel fusion protein constructs comprising a functional mitochondrial protein, that can enter mitochondria within intact cells. Further disclosed are methods of treating mitochondrial disorders by the disclosed fusion proteins and compositions therefor.
    Type: Application
    Filed: April 25, 2019
    Publication date: August 15, 2019
    Inventors: Haya Lorberboum-Galski, Hagar Greif
  • Publication number: 20190248847
    Abstract: A recombinant spider silk protein, consisting of no more than 800 amino acids, comprising a set of domains arranged according to the formula (NT)-REP-CT, wherein: the optional NT-domain, if present, comprises a sequence of 100 to 160 amino-acid residues derived from the N-terminal domain of a spider silk protein; the REP-domain comprises a sequence of 30 to 600 amino acid residues derived from the repetitive segment of a spider silk protein; and the CT-domain comprises a sequence of 70 to 120 amino acid residues derived from the C-terminal domain of a spider silk protein selected from: a sequence of 72 to 110 amino acid residues derived from the C-terminal domain of a spider silk protein, wherein the sequence comprises at least 7 residues independently selected from K, R, E and D; a sequence having at least 85% identity to SEQ ID NO: 15 or any one of SEQ ID NO:s 62-65 or 67-73; and a sequence having at least 70% identity to SEQ.
    Type: Application
    Filed: June 29, 2017
    Publication date: August 15, 2019
    Applicant: SPIBER TECHNOLOGIES AB
    Inventors: Anna Rising, Jan Johansson, Marlene Andersson
  • Publication number: 20190248848
    Abstract: Compositions and methods relating to synthetic modification of histone-binding proteins. Some histone-binding fusion-protein compositions include a modified polycomb chromodomain (PCD) motif, for example two tandem copies of the H3K27me3-binding PCD at the N-terminus separated by a linker. Some methods relate to multivalent engagement of one or more histone proteins or to tuning the activity of a synthetic histone-binding transcriptional regulator, for example by contacting the one or more histone proteins with a histone-binding fusion-protein composition having a modified PCD motif.
    Type: Application
    Filed: February 13, 2019
    Publication date: August 15, 2019
    Inventors: Karmella Haynes, Stefan Tekel
  • Publication number: 20190248849
    Abstract: The present invention is related to development of the improved cell-permeable (CP)-?SOCS3 recombinant protein which disrupt the interaction of leptin receptor (ObR) and suppressor of cytokine signaling 3 (SOCS3), as protein-based anti-obesity or anti-diabetes agent by utilizing the platform technology for macromolecule intracellular transduction.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 15, 2019
    Inventor: Daewoong JO
  • Publication number: 20190248850
    Abstract: The disclosure provides systems and methods useful for predicting or detecting a malfunction in a chromatography process in real-time. In some embodiments, the disclosure provides systems and methods for detecting an atypical profile in a process chromatogram in ion-exchange chromatography of a biologic product.
    Type: Application
    Filed: February 14, 2019
    Publication date: August 15, 2019
    Inventors: Nathan L. MAO, Scott CARVER, Bernhard SCHILLING, Eric SHIERLY
  • Publication number: 20190248851
    Abstract: The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Inventors: Kang TING, Chia SOO
  • Publication number: 20190248852
    Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. 5 The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.
    Type: Application
    Filed: May 24, 2017
    Publication date: August 15, 2019
    Applicants: Novo Nordisk A/S, Novo Nordisk A/S
    Inventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
  • Publication number: 20190248853
    Abstract: The present invention relates to methods for treating and/or preventing tumors and/or promoting apoptosis in a neoplastic cell comprising contacting the neoplastic cell with an cell-penetrating dominant-negative ATF5 (“CP-d/n-ATF5”), wherein the CP-d/n-ATF5 is capable of inhibiting ATF5 function and/or activity.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Inventors: Lloyd A. Greene, James Angelastro
  • Publication number: 20190248854
    Abstract: Methods for modifying a dystrophin gene are disclosed, for restoring dystrophin expression within a cell having an endogenous frameshift or nonsense mutation within the dystrophin gene. The methods comprise introducing a first cut within an exon en or intron of the dystrophin gene creating a first exon end or intron end, wherein said first cut is located upstream of the endogenous frameshift or nonsense mutation; and introducing a second cut within an exon or intron of the dystrophin gene creating a second exon end or intron end, wherein said second cut is located downstream of the frameshift or nonsense mutation. Upon joining/ligation of said first and second exon ends or intron ends a hybrid exon or intron junction is created and dystrophin expression is restored, as the correct reading frame is restored. Reagents and uses of the method are also disclosed, for example to treat a subject suffering from muscular dystrophy.
    Type: Application
    Filed: September 21, 2017
    Publication date: August 15, 2019
    Inventors: JACQUES P. TREMBLAY, JEAN-PAUL IYOMBE-ENGEMBE, PIERRE CHAPDELAINE, DANIEL AGUDELO, BENJAMIN DUCHÊNE
  • Publication number: 20190248855
    Abstract: The present invention is directed to modified CFTR proteins or fragments thereof that contain single or multiple amino acid mutations to improve the structural stability of such CFTR proteins and/or fragments. Specifically, the modified CFTR proteins or fragment thereof differ from the wild-type human CFTR protein or fragment thereof by the presence of four or more mutations selected from V150D, M470V, S492P, F494N, 5495P, A534P, I539T, G550E, G551D, R553Q, R555K, Q637R, 51255L, K1334G, 51359A, E1371Q, H14025, Q1411D, and any combination thereof, such that the stability of the polypeptide is increased relative to that of the wild-type human CFTR polypeptide or fragment thereof.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 15, 2019
    Inventors: John C. Kappes, Zhengrong Yang, Christie G. Brouillette, Ina L. Urbatsch
  • Publication number: 20190248856
    Abstract: Provided are Listeria-based immunogenic compositions comprising Wilms tumor protein (WT1) antigens and methods for treating and vaccinating against cancer and inducing an immune response against the same in a subject. Also provided herein are recombinant fusion polypeptides or chimeric polypeptides comprising Wilms tumor protein antigens, nucleic acids encoding such chimeric polypeptides or fusion polypeptides, recombinant bacteria or Listeria strains comprising such chimeric polypeptides or fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such chimeric polypeptides or fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such chimeric polypeptides or fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains.
    Type: Application
    Filed: June 30, 2017
    Publication date: August 15, 2019
    Applicant: Advaxis, Inc.
    Inventors: Michael Princiotta, Robert Petit
  • Publication number: 20190248857
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 15, 2019
    Inventors: Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • Publication number: 20190248858
    Abstract: The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 15, 2019
    Applicant: AskGene Pharma Inc.
    Inventors: Jian-Feng Lu, Yuefeng Lu, Aijun Wang, Donggou He, Kurt Shanebeck, Chen Yao
  • Publication number: 20190248859
    Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.
    Type: Application
    Filed: August 24, 2017
    Publication date: August 15, 2019
    Applicant: BRIM Biotechnology, Inc.
    Inventors: Frank Wen-Chi Lee, Kuanyin Karen Lin, Yeou-Ping Tsao, Tsung-Chuan Ho
  • Publication number: 20190248860
    Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.
    Type: Application
    Filed: December 13, 2018
    Publication date: August 15, 2019
    Inventors: Kenan Christopher Garcia, Aron Levin, Aaron Ring
  • Publication number: 20190248861
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 15, 2019
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Rakesh Datta, Zheng Xin Dong
  • Publication number: 20190248862
    Abstract: A nucleic acid sequence is provided that encodes a chimeric protein comprising a ligand that comprises a naturally occurring or modified follicle stimulating hormone sequence, e.g., an FSH? sequence, or fragment thereof, which ligand binds to human follicle stimulating hormone (FSH) receptor, linked to either (a) a nucleic acid sequence that encodes an extracellular hinge domain, a transmembrane domain, a co-stimulatory signaling region, and a signaling endodomain; or (b) a nucleic acid sequence that encodes a ligand that binds to NKG2D. The vector containing the nucleic acid sequence, the chimeric proteins so encoded, and modified T cells expressing the chimeric protein, as well as method of using these compositions for the treatment of FSHR-expressing cancers or tumor cells are also provided.
    Type: Application
    Filed: February 21, 2019
    Publication date: August 15, 2019
    Inventors: Alfredo Perales-Puchalt, Jose R. Conejo-Garcia
  • Publication number: 20190248863
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Application
    Filed: February 26, 2019
    Publication date: August 15, 2019
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIIVAN
  • Publication number: 20190248864
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding low density lipoprotein receptor comprising at least one mutation (e.g., an LDLR signally enhancing mutation).
    Type: Application
    Filed: April 30, 2019
    Publication date: August 15, 2019
    Inventors: Jeff Lynn ELLSWORTH, Joseph Beene BOLEN, Francine Marie GREGOIRE, Justin GUILD
  • Publication number: 20190248865
    Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.
    Type: Application
    Filed: October 21, 2016
    Publication date: August 15, 2019
    Inventors: Jingwei LU, Zhiyuan YANG, Cheng LIU, Hong LIU, Yiyang XU, Su YAN, Vivien Wai-Fan CHAN, Lucas HORAN
  • Publication number: 20190248866
    Abstract: This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use therof for treatment of immune related disorders and infections.
    Type: Application
    Filed: April 30, 2018
    Publication date: August 15, 2019
    Inventors: Amir TOPORIK, Avi Yeshah ROSENBERG, Galit ROTMAN, Zurit LEVINE, Iris HECHT
  • Publication number: 20190248867
    Abstract: Compositions for the treatment or prevention of multiple sclerosis are provided. In some embodiments, the composition comprises an isolated peptide comprising a partial amino acid sequence of a myelin oligodendrocyte glycoprotein (MOG) protein, wherein the peptide activates regulatory T cells. In some embodiments, the composition comprises dendritic cells pulsed with a MOG peptide that activates regulatory T cells. In some embodiments, the peptide activates HLA-E-restricted regulatory CD8+ T cells.
    Type: Application
    Filed: June 30, 2017
    Publication date: August 15, 2019
    Inventors: Xiaolei TANG, David J. BAYLINK
  • Publication number: 20190248868
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 15, 2019
    Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
  • Publication number: 20190248869
    Abstract: A nucleic acid molecule comprising a nucleotide sequence encoding an inhibitory chimeric antigen receptor (i CAR) capable of preventing or attenuating undesired activation of an effector immune cell, wherein the i CAR comprises an extracellular domain that specifically binds to a single allelic variant of a polymorphic cell surface epitope absent from mammalian tumor cells due to loss of heterozygosity (LOH) but present at least on all cells of related mammalian normal tissue; and an intracellular domain comprising at least one signal transduction element that inhibits an effector immune cell is provided. Vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided.
    Type: Application
    Filed: September 28, 2017
    Publication date: August 15, 2019
    Inventors: Gideon Gross, Merav Beiman, William Gibson
  • Publication number: 20190248870
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?7 binding.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • Publication number: 20190248871
    Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.
    Type: Application
    Filed: October 26, 2017
    Publication date: August 15, 2019
    Inventors: Joon Won LEE, Won Yong HAN, Su Jung KIM, Jun Seok OH, So Young KIM, Kwang Woo KIM, Yeon Kyeong SHIN
  • Publication number: 20190248872
    Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10Fn3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.
    Type: Application
    Filed: January 22, 2019
    Publication date: August 15, 2019
    Inventors: Ray Camphausen, Amna Saeed-Kothe, Jonathan Davis, Tracy S. Mitchell
  • Publication number: 20190248873
    Abstract: Some embodiments of the systems, methods and compositions provided herein relate to a compound protease. In some embodiments, the compound protease includes a protease domain and a cut site for another enzyme. In some embodiments, the compound protease includes an association domain. In some embodiments, the compound protease is part of a protein circuit.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 15, 2019
    Inventors: Xiaojing Gao, Lucy S. Chong, Michael Elowitz, Mark William Budde, Matthew Sun-min Kim
  • Publication number: 20190248874
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Application
    Filed: November 1, 2018
    Publication date: August 15, 2019
    Inventor: Antonio Lanzavecchia
  • Publication number: 20190248875
    Abstract: Provided herein are a mutant envelope protein of Zika virus and a nucleic acid molecule including a nucleotide sequence encoding the mutant envelope protein. The mutant envelope protein, which preferably has a threonine substitution at 105th position, or an asparagine substitution at 248th position and a threonine substitution at 250th position in an amino acid sequence of SEQ ID NO: 1, includes an N-glycan masking a fusion loop region of the mutant envelope protein of Zika virus. Also provided herein is a vaccine composition, including the mutant envelope protein or a recombinant virus including the nucleic acid molecule. Also provided herein is a method of preventing Zika virus infection and reducing antibody-dependent enhancement of dengue virus infection, including administering to a subject in need thereof an effective amount of a vaccine composition including the mutant envelope protein of Zika virus.
    Type: Application
    Filed: July 17, 2018
    Publication date: August 15, 2019
    Inventors: Suh-Chin Wu, Shao-Ping Yang, Hsiao-Han Lin
  • Publication number: 20190248876
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Inventors: Victor J. TORRES, Tamara REYES-ROBLES, Francis ALONZO, III
  • Publication number: 20190248877
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one antigen binding moiety capable of specific binding to Tenascin-C (TnC) and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: November 9, 2018
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • Publication number: 20190248878
    Abstract: The present invention provides: an antibody which specifically bonds to human NINJ-1; and a fragment thereof. The antibody or the fragment thereof according to the present invention has very high bonding affinity and bonding specificity with respect to a human NINJ-1 or a homogeneous binding site of the protein, and does not exhibit cross-reactivity with NINJ-1 proteins that are derived from other organisms and have high protein similarity. Accordingly, the present invention provides significant advantages with respect to accuracy and sensitivity and the like, not only in diagnosing disease related to NINJ-1 proteins but also in inhibiting pathological conditions involving NINJ-1 proteins. In particular, the antibody provided according to the present invention has a remarkable effect of inhibiting attachment between immunocytes and human cerebral endothelial cells, and thus has an effect of treating multiple sclerosis.
    Type: Application
    Filed: August 28, 2017
    Publication date: August 15, 2019
    Inventors: Young Kee SHIN, Seahyung LEE, Kyoung SONG, Ji Hye LEE
  • Publication number: 20190248879
    Abstract: The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using said mutant p53 polypeptide as an immunogen wherein said polypeptide comprises: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration, in particular wherein the scaffold sequence is thioredoxin. In the specific embodiments, antibodies against mutant p53 comprising R175H, R248Q or R273H are generated. Also disclosed are the uses of said antibodies for diagnosis, prognosis and stratification of patient groups and further encompasses the use of antibodies for imaging and treatment of cancer.
    Type: Application
    Filed: October 17, 2017
    Publication date: August 15, 2019
    Inventors: Tr Kanaga Sabapathy, David P. Lane, Le-Ann Hwang, Xin Yu Koh, Liew Oi Wah
  • Publication number: 20190248880
    Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.
    Type: Application
    Filed: April 22, 2019
    Publication date: August 15, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Jeffrey Baron, Crystal Sao Fong Cheung, Julian Chun Kin Lui, Dimiter Dimitrov, Zhongyu Zhu
  • Publication number: 20190248881
    Abstract: The present invention provides TGF-? antagonists and conjugates thereof, as well as methods of using such compositions for attenuating TGF-? signaling. These novel compositions and methods may be useful for treating individuals suffering from devastating diseases associated with elevated TGF-? signaling, including skeletal disorders, such as osteogenesis imperfecta (OI), and muscular diseases, such as muscular dystrophies.
    Type: Application
    Filed: December 4, 2018
    Publication date: August 15, 2019
    Inventors: Philippe CRINE, Susan SCHIAVI
  • Publication number: 20190248882
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
    Type: Application
    Filed: April 16, 2019
    Publication date: August 15, 2019
    Inventors: Yanbin Liang, Daniel W. Gil
  • Publication number: 20190248883
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: February 20, 2019
    Publication date: August 15, 2019
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, D.M.Sc., Debra HUDSON, Jørgen PETERSEN
  • Publication number: 20190248884
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Application
    Filed: February 25, 2019
    Publication date: August 15, 2019
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20190248885
    Abstract: Provided are methods of modulating neuronal and/or oligodendrocyte survival. The subject methods relate to preventing neuronal and/or oligodendrocyte death or increasing neuron or oligodendrocyte death. Also provided are neuroprotective compositions and neurotoxic compositions. Methods of identifying neurotoxins, methods of identifying neurotoxin inhibitors and methods of identifying neurotoxin conditions in a subject are also provided.
    Type: Application
    Filed: October 25, 2017
    Publication date: August 15, 2019
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Shane Antony Liddelow, Kevin Guttenplan, Ben A. Barres
  • Publication number: 20190248886
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 15, 2019
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Publication number: 20190248887
    Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
    Type: Application
    Filed: November 15, 2018
    Publication date: August 15, 2019
    Inventors: James R. Prudent, Jon S. Thorson
  • Publication number: 20190248888
    Abstract: The present invention provides glucagon signaling pathway antagonists for use in combination with amino acid transport inhibitors, or mTOR inhibitors for lowering blood glucose levels in patients suffering from a disease or condition characterized in part by elevated blood glucose levels. According to certain embodiments of the invention, the glucagon signaling pathway antagonists are fully human antibodies that bind to human GCG or human GCGR. The antibodies of the invention, when combined with either SLC38A5 inhibitors or with an mTOR inhibitor are useful for lowering blood glucose levels, without resulting in alpha cell hyperplasia, and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 15, 2019
    Inventors: Jinrang Kim, Haruka Okamoto, Andrew J. Murphy, Jesper Gromada, George D. Yancopoulos
  • Publication number: 20190248889
    Abstract: The invention provides anti-LgR5 antibodies and methods of using the same.
    Type: Application
    Filed: April 22, 2019
    Publication date: August 15, 2019
    Applicant: GENENTECH, INC.
    Inventors: Andrew G. Polson, Weiguang Mao, Ron Firestein
  • Publication number: 20190248890
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 15, 2019
    Applicant: UCB Biopharma SPRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Publication number: 20190248891
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 15, 2019
    Inventor: Michael C. Jensen
  • Publication number: 20190248892
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemic-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.
    Type: Application
    Filed: February 28, 2019
    Publication date: August 15, 2019
    Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20190248893
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Application
    Filed: July 13, 2017
    Publication date: August 15, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Y. HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
  • Publication number: 20190248894
    Abstract: This disclosure provides compositions and related methods providing targeted cell-specific inhibition of Notch receptor signaling. The disclosure provides a bi-specific molecule with separate domains that target the intended cell-type and the Notch receptor on that cell-type. The disclosure also provides for nucleic acids, vectors, and cells allowing for the expression of the bi-specific fusion molecules. The disclosure also provides related methods of making and using the bi-specific fusion molecule to inhibit Notch signaling in target cells of interest, including for the treatment of diseases characterized by a dysregulation of Notch signaling.
    Type: Application
    Filed: July 20, 2017
    Publication date: August 15, 2019
    Applicants: Fred Hutchinson Cancer Research Center, The Board of Trustees of The Leland Stanford Junior University
    Inventors: Irwin Bernstein, Vincent Luca, Kenan Christopher Garcia
  • Publication number: 20190248895
    Abstract: This disclosure relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 15, 2019
    Inventors: CARINE PATUREL, HELENE SICARD